OBJECTIVES: Early-onset Alzheimer disease (EOAD) diagnosis often represents a challenge because of the high frequency of atypical presentations. Our aim was to describe the clinical features, APOE genotype, and its pathologic correlations of neuropathologic confirmed EOAD. METHODS: Retrospective review of clinical data (age at onset, family history, clinical presentation, diagnostic delay, diagnosis) and APOE genotype of patients with neuropathologically confirmed EOAD (<60 years). RESULTS: Forty cases were selected. Mean age at onset was 54.5 years (range 46-60). The mean disease duration was 11 years with a mean diagnostic delay of 3.1 years. A total of 37.5% had a nonmemory presentation. Behavioral/executive dysfunction was the most prevalent atypical presentation. Incorrect initial clinical diagnoses were common (53%) in patients with atypical presentations, but rare when anterograde amnesia was the presenting symptom (4%). The incorrect initial clinical diagnoses were 2 behavioral variant frontotemporal lobar degeneration, 2 normal pressure hydrocephalus, 1 semantic dementia, 1 primary progressive aphasia, 1 corticobasal degeneration, 1 pseudodementia with depression, and 1 unclassifiable dementia. APOE genotype was ε3/ε3 in 59%, with no significant differences between typical and atypical presentations. APOE ε4 was 3.3 times more frequent in subjects with family history of AD. A total of 97.5% of the cases presented advanced neurofibrillary pathology. A total of 45% of the patients had concomitant Lewy body pathology although localized in most cases and without a significant clinical correlate. CONCLUSION: One third of patients with pathologic confirmed EOAD presented with atypical symptoms. Patients with EOAD with nonamnestic presentations often receive incorrect clinical diagnoses.
OBJECTIVES: Early-onset Alzheimer disease (EOAD) diagnosis often represents a challenge because of the high frequency of atypical presentations. Our aim was to describe the clinical features, APOE genotype, and its pathologic correlations of neuropathologic confirmed EOAD. METHODS: Retrospective review of clinical data (age at onset, family history, clinical presentation, diagnostic delay, diagnosis) and APOE genotype of patients with neuropathologically confirmed EOAD (<60 years). RESULTS: Forty cases were selected. Mean age at onset was 54.5 years (range 46-60). The mean disease duration was 11 years with a mean diagnostic delay of 3.1 years. A total of 37.5% had a nonmemory presentation. Behavioral/executive dysfunction was the most prevalent atypical presentation. Incorrect initial clinical diagnoses were common (53%) in patients with atypical presentations, but rare when anterograde amnesia was the presenting symptom (4%). The incorrect initial clinical diagnoses were 2 behavioral variant frontotemporal lobar degeneration, 2 normal pressure hydrocephalus, 1 semantic dementia, 1 primary progressive aphasia, 1 corticobasal degeneration, 1 pseudodementia with depression, and 1 unclassifiable dementia. APOE genotype was ε3/ε3 in 59%, with no significant differences between typical and atypical presentations. APOE ε4 was 3.3 times more frequent in subjects with family history of AD. A total of 97.5% of the cases presented advanced neurofibrillary pathology. A total of 45% of the patients had concomitant Lewy body pathology although localized in most cases and without a significant clinical correlate. CONCLUSION: One third of patients with pathologic confirmed EOAD presented with atypical symptoms. Patients with EOAD with nonamnestic presentations often receive incorrect clinical diagnoses.
Authors: Bradford C Dickerson; Scott M McGinnis; Chenjie Xia; Bruce H Price; Alireza Atri; Melissa E Murray; Mario F Mendez; David A Wolk Journal: CNS Spectr Date: 2017-02-15 Impact factor: 3.790
Authors: Kevin R Krull; Deepa Bhojwani; Heather M Conklin; Deqing Pei; Cheng Cheng; Wilburn E Reddick; John T Sandlund; Ching-Hon Pui Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Jennifer L Whitwell; Jonathan Graff-Radford; Nirubol Tosakulwong; Stephen D Weigand; Mary Machulda; Matthew L Senjem; Christopher G Schwarz; Anthony J Spychalla; David T Jones; Daniel A Drubach; David S Knopman; Bradley F Boeve; Nilüfer Ertekin-Taner; Ronald C Petersen; Val J Lowe; Clifford R Jack; Keith A Josephs Journal: Ann Neurol Date: 2018-02-06 Impact factor: 10.422
Authors: Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant Journal: Alzheimers Dement Date: 2018-12-13 Impact factor: 21.566
Authors: Rik Ossenkoppele; Yolande A L Pijnenburg; David C Perry; Brendan I Cohn-Sheehy; Nienke M E Scheltens; Jacob W Vogel; Joel H Kramer; Annelies E van der Vlies; Renaud La Joie; Howard J Rosen; Wiesje M van der Flier; Lea T Grinberg; Annemieke J Rozemuller; Eric J Huang; Bart N M van Berckel; Bruce L Miller; Frederik Barkhof; William J Jagust; Philip Scheltens; William W Seeley; Gil D Rabinovici Journal: Brain Date: 2015-07-02 Impact factor: 13.501
Authors: Josephine Barnes; Bradford C Dickerson; Chris Frost; Lize C Jiskoot; David Wolk; Wiesje M van der Flier Journal: Alzheimers Dement Date: 2015-04-24 Impact factor: 21.566